Prof Fei Yu, Shanghai tenth people’s hospital, China
Prof. Fei Yu, a distinguished expert in Nuclear Medicine, holds a rich educational background with degrees from Soochow University and Fudan University. With a graduation date of June 2012 from Soochow University School of Medicine, he has dedicated himself to advancing the field of Nuclear Medicine through significant contributions and research.
Publication profile
Scopus
Education
Prof. Fei Yu graduated in June 2012 from Soochow University, where he completed his medical education. He previously attended Fudan University from September 1996 to July 2001, earning his degree from the School of Public Health and Community Medicine. Furthering his studies, Prof. Yu obtained his degree from Tongji University’s School of Medicine between March 2005 and March 2008. With a strong foundation in public health and medicine, he has made significant contributions to his field. 🌍📚🏥
Honors and Awards
Prof. Fei Yu is a distinguished researcher recognized for his significant contributions to nuclear medicine. He was awarded the Star of Hope Award by the Chinese Society of Nuclear Medicine in September 2018. His project on targeted therapy for non-small cell lung cancer, supported by the Shanghai Talent Development Fund in September 2017, highlights his innovative approach in the field. He also received the Shanghai Science and Technology Award in November 2010 for developing a 99mTc labeled somatostatin receptor imaging kit for lung cancer diagnosis. Additionally, he was honored with the Huaxia Medical Science and Technology Award and the Hospital Technology Innovation Award for his research on medical ethics and intelligent clinical pathways. 🌟🔬🏆
Research Achievements
Dr. Yang and colleagues have made significant strides in cancer therapy and cardiology. Their 2024 study in Theranostics explores how damaged mitochondrial transfer impacts the bystander effect induced by alpha-particle radiation (🎗️). Another study published in Small reveals that alpha-emitter Radium-223 triggers STING-dependent pyroptosis, enhancing antitumor immunity (💉). Additionally, they developed alpha radionuclide-chelated radioimmunotherapy promoters to advance local radiotherapy strategies, published in Biomaterials Research (📚). In cardiology, their nomogram for predicting major adverse cardiac events in patients with ischemia, featured in Frontiers in Cardiovascular Medicine, is a pivotal contribution (❤️).
Research focus
Prof. Fei Yu is a prominent researcher specializing in nuclear medicine and molecular imaging. His work encompasses the development and evaluation of advanced therapeutic approaches, particularly in the context of neuroendocrine tumors and thyroid cancer. Prof. Yu’s research focuses on innovative treatments like peptide receptor radionuclide therapy and the mechanisms of antitumor immunity, including the role of STING-dependent pyroptosis induced by alpha-emitter Radium-223. His contributions significantly enhance understanding of cancer therapies and their implications for patient prognosis. 🔬💉📈
Memberships and Leadership
Prof. Yu is an active member of several professional societies, holding key positions such as Vice Chairman of the Continuing Education Committee of Nuclear Medicine under the Chinese Nuclear Society. His involvement in these organizations reflects his dedication to the growth and education within the field, emphasizing the importance of collaboration and knowledge sharing.
Funding and Research Projects
Prof. Yu leads multiple funded projects, including the National Natural Science Foundation project on interstitial radiotherapy combined with immunotherapy for non-small cell lung cancer. His work is characterized by a strong focus on innovative therapies that integrate radiological techniques with emerging treatment modalities.
Publication top notes
Triglyceride-glucose index is associated with myocardial ischemia and poor prognosis in patients with ischemia and no obstructive coronary artery disease
The D-SPECT SH reconstruction protocol: improved quantification of small left ventricle volumes
The Effect of Radioiodine Therapy on the Prognosis of Differentiated Thyroid Cancer with Lung Metastases
Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles
Alpha-Emitter Radium-223 Induces STING-Dependent Pyroptosis to Trigger Robust Antitumor Immunity
Conclusion
Prof. Fei Yu exemplifies excellence in nuclear medicine, with a career marked by substantial research contributions, leadership roles, and a commitment to advancing medical science. His innovative approaches to cancer therapy and active involvement in professional societies make him an outstanding candidate for the Best Researcher Award. Prof. Yu’s dedication to improving patient outcomes through research and education sets a high standard for future professionals in the field.